A phase II open-label study of cetuximab in unresectable hepatocellular carcinoma: Final results
2007
4598 Background: Hepatocellular carcinoma (HCC) express the epidermal growth factor receptor (EGFR), and EGFR-targeting therapies are known to block tumor growth. We tested the activity of cetuxima...
Keywords:
- Correction
- Source
- Cite
- Save
- Machine Reading By IdeaReader
0
References
74
Citations
NaN
KQI